Vera, K., Djafari, L., Faivre, S., Djazouli, K., Osorio, M., ...
Background: Temozolomide has shown activity and limited toxicity in patients with primary brain tumors at doses of 150–200 mg/m2/day on days 1–5 every 4 weeks. In this study, a new alternative...
Geoerger, B, Vassal, G, Doz, F, O'Quigley, J, Wartelle, M, Watson, A J, ...
Cisplatin may have additive activity with temozolomide due to ablation of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (MGMT). This phase I/II study determined recommended combination...